14 results about "Diphtheria" patented technology

The invention particularly relates to a diphtheria toxin antigen modified by fatty acid and application thereof, and belongs to the field of biological medicine, in the diphtheria toxin antigen modified by fatty acid, the fatty acid modification comprises N-terminal cysteine (Cys) modified by fatty acid, the N-terminal Cys modified by fatty acid is characterized in that sulfydryl containing Cys is modified by diacylglycerol and / or alpha amino is modified by fatty acyl. Compared with the existing diphtheria toxin protein antigen, the fatty acid modified diphtheria toxin antigen not only has faster induction and higher immune protection effect than the conventional intramuscular injection induction of the existing diphtheria toxin antigen, but also can induce respiratory tract mucosa immunity, and provides a basis for blocking diphtheria infection and diffusion propagation and providing a vaccine for immunoprophylaxis.

The invention provides a pertussis (five components), diphtheria and tetanus combined vaccine, and particularly relates to a pertussis and tetanus combined vaccine with improved immune response. The immunogenic composition and the vaccine provided by the invention contain specially selected double aluminum-based adjuvants, so that the prepared composition vaccine can induce an organism to generate a good immune response, and meanwhile, the safety of the vaccine is ensured.

The present invention describes a second-generation tetanus toxoid vaccine and a process for the preparation thereof, comprising the steps of: inducing an E. coli culture OD600=0.5 by adding 0.2 mM IPTG; growing the culture at 14-16° C. for 14 to 20 hours; suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride; adding 1% of triton-X-100 to the phosphate buffer, and adding the buffer to the culture; sonicating the culture for a period of 3 minutes (at 5 sec on / off pulse) at 4° C. on cold beads; centrifuging the culture for 60 to 90 minutes; collecting and purifying a supernatant using Ni-NTA affinity column with an eluant; and combining the supernatant into a pool with contaminated bands and concentrating using Centriprep-30 centrifuge filters (30 kDa pores).

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention provides an attenuated pertussis CS recombinant bacterium, the CS recombinant bacterium is obtained by mutating a ninth arginine residue of an S1 subunit in a CS strain with a preservation number of CMCC 58003 into a lysine residue and mutating a 129th glutamic acid residue into a glycine residue, and the amino acid sequence of the S1 subunit of the CS recombinant bacterium is as shown in SEQ ID NO.1. The invention further provides a preparation method of the attenuated pertussis CS recombinant bacterium. The method for constructing the recombinant bacteria comprises the following steps: constructing recombinant plasmids; preparing competent cells of the wild pertussis CS strain; electrically transferring the recombinant plasmid into competent cells of the wild pertussis CS strain; respectively preparing BG sheep blood screening plates containing Amp and DOG; sequentially screening a first round and a second round of recombinant pertussis CS strains; and preparing the two-round recombinant pertussis CS strain into a competent strain, and screening twice according to the same steps to obtain the attenuated pertussis CS recombinant strain. The constructed recombinant bacteria can efficiently obtain detoxified PT, and can be applied to products for treating, detecting and preventing pertussis diseases.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The present disclosure is directed to fusion proteins and propeptide fusions comprising a diphtheria toxin catalytic domain and translocation domain with a receptor binding domain from a Clostridial neurotoxin. The fusion protein has a therapeutic cargo positioned upstream of the catalytic domain. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.

The application discloses a preparation method and application of a cocktail vaccine of Acinetobacter baumannii, and belongs to the technical field of vaccine preparation. The vaccine comprises sugar conjugates formed by coupling three branched pentasaccharides of K14, K47 and K128 with diphtheria toxoid. The preparation method comprises the steps of hapten synthesis, purification, coupling with carrier protein and mixing. Experiments show that the vaccine can induce high levels of specific antibodies, significantly reduce the tissue bacterial load of mice infected with Acinetobacter baumannii, and has a wide protective effect. The application is suitable for preventing and treating various infectious diseases caused by Acinetobacter baumannii.

The invention provides an immunogenic composition and a pertussis (three components), diphtheria and tetanus combined vaccine, and particularly relates to a pertussis-pertussis vaccine capable of improving immune response. The immunogenic composition and the vaccine provided by the invention contain specially selected double aluminum-based adjuvants, so that the prepared composition vaccine can induce an organism to generate a good immune response, and meanwhile, the safety of the vaccine is ensured.

The invention discloses a pathogen infection diagnosis marker based on DPH gene family mRNA and diphtheria amide modification level, a kit and application. The marker combination comprises the mRNA expression level of the DPH1-DPH7 gene and the diphtheria amide modification level of the eukaryotic elongation factor 2. The invention reveals that the combination is remarkably related to pathogen infection for the first time, and provides a detection kit containing a specific primer, biotinylated NAD, pseudomonas exotoxin A and other reagents. The indexes are respectively detected through qPCR (quantitative polymerase chain reaction) and non-denatured immunoblotting, and efficient diagnosis can be realized through combined analysis. Experiments show that the combined marker is excellent in diagnostic performance, the area AUC under a curve of a combined logistic regression model can reach 0.917, the sensitivity is 90.9%, the specificity is 85.7%, and a novel and reliable molecular scheme is provided for early-stage differential diagnosis of infection.

The present invention relates to a process of purifying a protein. Specifically, the present invention relates to a process of purification of a polyclonal antibody and / or antibody fragments. The present invention employs an adsorptive separation using anion exchange chromatography and cation exchange chromatography along with ultrafiltration and diafiltration to achieve high-purity antibody / or antibody fragments. The process provided in the present invention is applicable for polyclonal antibody and / or antibody fragments, which are associated with conditions but not limited to snake envenomation, scorpion envenomation, diphtheria infection, tetanus infection, rabies virus infection and gas gangrene infection due to Clostridium species.

Technical Area: This study specifically focuses on a screening and clinical evaluation system developed for screening for endometriosis in adolescent girls, identifying at-risk individuals and referring them to gynecologists, thus enabling early diagnosis of endometriosis. The problem that needs to be solved: Endometriosis, the most significant pathological cause of severe dysmenorrhea (painful menstruation) and chronic pelvic pain in adolescents, severely restricts individuals' daily physical and psychosocial functioning. Endometriosis is a chronic and progressive disease with an average diagnosis time of 7-10 years from the onset of the first symptoms. The main reasons for this significant delay in diagnosis are as follows: 1. Definitive diagnosis often requires invasive / surgical methods. 2. The fact that classic diagnostic parameters specific to the adult age group (infertility and dyspareunia / painful intercourse) are not applicable to the adolescent population, which is around 13 years of age, 3. The acceptance and normalization of painful menstruation during adolescence as "normal" by society and / or healthcare providers. These factors often lead to undiagnosed cases in adolescence, causing significant diagnostic delays within the healthcare system. Solution to the problem: Early diagnosis of endometriosis is critical to preventing disease progression, the development of chronic pelvic pain, and long-term sequelae (infertility, etc.). In this regard, age groups where all individuals have regular and predictable contact with the health system offer a strategic window of opportunity for effective community-based screening. In Turkey, under the National Childhood Immunization Schedule, the adult-type diphtheria-tetanus (Td) booster vaccine is routinely administered at age 13, and this vaccination is carried out in family health centers. Therefore, age 13 is an important period when healthy girls are re-engaged with the health system in a planned manner and benefit from routine preventive health services.This application could be used as an opportunity to evaluate an easy, quick, low-cost, and acceptable endometriosis screening test that can be administered during the same visit. This would allow for the identification of potential cases before the disease reaches advanced stages and referral of girls requiring further evaluation to appropriate healthcare facilities. Characteristics of the proposed method: Neither in our country nor in foreign literature is there a standardized screening questionnaire / system specific to the adolescent age group and suitable for integration into routine preventive health services. In this study, a standard endometriosis screening questionnaire, suitable for integration into primary health care services and at a level appropriate to the perception of 13-year-old girls, was prepared to identify individuals at risk for endometriosis. The questionnaire consists of a total of 9 questions: 6 aimed at determining the presence of the disease, and 3 aimed at determining its severity and the extent to which it impairs functionality. As previously mentioned, this program is not intended for diagnosis, but rather a decision support and risk scoring algorithm that classifies adolescents as high-risk and low-risk and directs them to medical services. This project is named the ENDONÜÇ PROJECT, inspired by combining the first four letters of "endometriosis" with the age of 13. The patent application in question is being filed to patent this project and the screening questionnaire.

The present disclosure relates to a system (100) for the detection of bacterial infection in humans. The system comprises an outer surface (101), a pressure-sensitive polyurethane film (103), a microfluidic channel (105), at least one marker (106) and an outlet for removing an excess biofluid (102). The system optionally comprises a lateral flow test strip (200). The system is safe, uses specific antigen-antibody interaction, is accurate, non-invasive allows rapid detection / screening of tuberculosis patients, and is easy to handle without health workers. Further, the present disclosure relates to a method for point-of-care detection of bacterial infection with or without a lateral flow strip (200). The method is specific, non-invasive, rapid, simple, has greater patient compliance and requires less attention from a health care assistant. The system and the method are specifically used to detect Tuberculosis, Anthrax, Tetanus, Pneumonia, Cholera, Diphtheria, Typhoid and Typhus.